55 episodes

Expert insight and analysis providing information directly relevant to cystic fibrosis care, through topic-focused newsletters summarizing the peer-reviewed literature and accompanying podcasts to illustrate how to apply that information in the clinic.

eCysticFibrosis Review eCysticFibrosis Review

    • Medicine
    • 3.5, 2 Ratings

Expert insight and analysis providing information directly relevant to cystic fibrosis care, through topic-focused newsletters summarizing the peer-reviewed literature and accompanying podcasts to illustrate how to apply that information in the clinic.

    Addressing Mental Health in CF

    Addressing Mental Health in CF

    Take our post-test to claim CME credits.







    To read a companion newsletter click here.







    Anxiety and depression in cystic fibrosis — who do these conditions affect? How much do they influence patient health? How can clinicians identify and manage them? What evidence-based interventions have been shown to work?







    In this issue, Dr. Anna Georgiopoulos, Assistant Professor of Psychiatry, Part-Time, Harvard Medical School and Consulting Psychiatrist, Massachusetts General Hospital Cystic Fibrosis Program, takes us to the clinic to answer these questions that can be key to the health and well-being of children, adults, and families living with CF.

    • 20 min
    Clinical Considerations: New Anti-Inflammatories & New CFTR Modulators

    Clinical Considerations: New Anti-Inflammatories & New CFTR Modulators

    New CFTR modulators for F508del mutations? New research into reducing inflammation in the CF lung?  In this issue, Dr. Jennifer Taylor-Cousar from National Jewish Health in Denver explains the potential clinical impact of new and emerging CF disease modifying therapies.







    Take our post-test to claim CME credits.







    To read a companion newsletter click here.

    • 21 min
    Continuous Alternating Therapies: A Clinical Perspective

    Continuous Alternating Therapies: A Clinical Perspective

    Volume 8, Issue 11.







    In this issue:







    Inhaled antibiotics have become the foundation of treating chronic respiratory tract Pseudomonas infection in individuals with cystic fibrosis. But what happens when inhaled monotherapy doesn’t sufficiently manage the symptoms? Which patients are appropriate candidates for treatment with multiple inhaled agents?  Which medications are appropriate for continuous alternating therapy (CAT)?







    In this Issue, Dr. Elliott Dasenbrook from the Cleveland Clinic brings the evidence he analyzed in his recent eCysticFibrosis Review Newsletter issue (Vol 8; Issue 10) into the clinic to help guide clinical decision-making.







    Take our post-test to claim CME credits.







    To read a companion newsletter click here.

    • 21 min
    In The Clinic: CFTR Modification & Nutritional Deficiencies

    In The Clinic: CFTR Modification & Nutritional Deficiencies

    Volume 8, Issue 9.







    In this issue:







    The effects of CFTR modifiers on improving lung function in people with cystic fibrosis are well known. But what about their effects on the GI tract that directly affect nutrition?







    In this issue, Dr. Michael Wilschanski — Director of Hadassah Hospital’s Pediatric Gastroenterology Unit at Hebrew University in Jerusalem — explains how new findings about CFTR modification can impact clinical practice.







    Take our post-test to claim CME credits.







    To read a companion newsletter click here.

    • 17 min
    Clinical Insight: CFTR Modulators

    Clinical Insight: CFTR Modulators

    Volume 8, Issue 6.











    In this issue, Dr. Gregory Sawicki — Associate Professor of Pediatrics at Harvard Medical School and Director of the Cystic Fibrosis Center at Boston Children’s Hospital — discusses how the recent findings about the real-world use of CFTR modulators can impact clinical practice.











    Take our post-test to claim CME credits.







    To read a companion newsletter click here.

    • 28 min
    Clinical Approaches to MDR Lung Infections

    Clinical Approaches to MDR Lung Infections

    Volume 8, Issue 4.







    Multidrug resistant lung infections present an increasingly common and increasingly dangerous threat to all individuals with cystic fibrosis.  Common CF pathogens — Pseudomonas aeruginosa, Burkholderia cepacia complex, Achromobacter xylosoxidans, Stenotrophomonas maltophilia — are all showing increasing resistance to clinicians’ usual antibiotic armamentarium.







    In this issue, Dr. Claire Elson, from the University of Missouri Kansas City School of Pharmacy, and Dr. Christopher Oermann, from the UMKC School of Medicine, describe strategies for the clinical management of these resistant infections.







    Take our post-test to claim CME credits.







    To read a companion newsletter click here.

    • 22 min

Customer Reviews

3.5 out of 5
2 Ratings

2 Ratings

andefined ,

Testing

Testing

Top Podcasts In Medicine